Takeda Pharmaceutical Company Ltd

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

A Study of Soticlestat and Rifampin in Healthy Adults

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Soticlestat
Drug: Rifampin

First Posted Date: 2021-10-28

Last Posted Date: 2023-11-22

Lead Sponsor: Takeda

Target Recruit Count: 15

Registration Number: NCT05098041

Locations: 🇬🇧
Celerion, Belfast, United Kingdom

A Study of TAK-771 in Japanese Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN)

Phase 3

Active, not recruiting

Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Multifocal Motor Neuropathy (MMN)

Interventions: Drug: TAK-771

First Posted Date: 2021-10-19

Last Posted Date: 2024-04-01

Lead Sponsor: Takeda

Target Recruit Count: 26

Registration Number: NCT05084053

Locations: 🇯🇵
Asahikawa Medical Center, Asahikawa, Hokkaido, Japan
🇯🇵
Tokushima National Hospital, Yoshinogawa, Tokushima, Japan
🇯🇵
Chiba University Hospital, Chiba, Japan

and more 20 locations

A Study Reviewing Medical Records of Adults With Helicobacter Pylori Infections in China

Completed

Conditions: Helicobacter Pylori

First Posted Date: 2021-10-11

Last Posted Date: 2023-04-18

Lead Sponsor: Takeda

Target Recruit Count: 23000

Registration Number: NCT05073367

Locations: 🇨🇳
Army Medical Center of PLA, Chongqing, Sichuan, China
🇨🇳
Zhejiang Provincial Peoples Hospital, Hangzhou, Zhejiang, China
🇨🇳
Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China

and more 2 locations

A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

Phase 1

Recruiting

Conditions: Hepatocellular Cancer
Breast Cancer
Kidney Cancer
Squamous Cell Cancer of Head and Neck (SCCHN)
Non-small Cell Lung Cancer (NSCLC), Non-squamous
Gastric Cancer
Esophageal Cancer
Nasopharyngeal Cancer
Mesothelioma
Pancreatic Cancer

Interventions: Drug: TAK-500
Drug: Pembrolizumab

First Posted Date: 2021-10-07

Last Posted Date: 2024-08-26

Lead Sponsor: Takeda

Target Recruit Count: 313

Registration Number: NCT05070247

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸
University of California San Diego, La Jolla, California, United States

and more 9 locations

A Study of Soticlestat With Itraconazole and Mefenamic Acid in Healthy Adults

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Soticlestat
Drug: Mefenamic acid
Drug: Itraconazole

First Posted Date: 2021-10-01

Last Posted Date: 2023-10-03

Lead Sponsor: Takeda

Target Recruit Count: 28

Registration Number: NCT05064449

Locations: 🇺🇸
Celerion, Lincoln, Nebraska, United States

A Study of TAK-881 in Healthy Adults

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Biological: TAK-881

First Posted Date: 2021-09-28

Last Posted Date: 2024-01-12

Lead Sponsor: Takeda

Target Recruit Count: 24

Registration Number: NCT05059977

Locations: 🇺🇸
Clinical Pharmacology of Miami, Hialeah, Florida, United States

A Study of Elaprase in Children and Adults With Hunter Syndrome (Mucopolysaccharidosis II) in India

Phase 4

Completed

Conditions: Hunter Syndrome

Interventions: Biological: Elaprase

First Posted Date: 2021-09-27

Last Posted Date: 2024-11-19

Lead Sponsor: Takeda

Target Recruit Count: 5

Registration Number: NCT05058391

Locations: 🇮🇳
JK Lone Hospital, Jaipur, Rajasthan, India
🇮🇳
Institute of Child Health, Kolkata, India
🇮🇳
SAT Hospital - Govt Medical College, Thiruvananthapuram, Kerala, India

and more 2 locations

A Study of Real-World Outcomes of People With Crohn's Disease (CD)

Completed

Conditions: Crohn Disease

First Posted Date: 2021-09-24

Last Posted Date: 2022-10-21

Lead Sponsor: Takeda

Target Recruit Count: 623

Registration Number: NCT05056441

Locations: 🇦🇺
Concord Repatriation General Hospital, Concord, New South Wales, Australia
🇦🇺
Mater Misericordiae Health Services, South Brisbane, Queensland, Australia
🇦🇺
Integrated Gut Health Pty Ltd, Taringa, Queensland, Australia

and more 28 locations

An Additional Analysis of Data from the PARADIGM Exploratory Study (NCT02394834) in Patients with Advanced/Recurrent Colorectal Cancer

Active, not recruiting

Conditions: Colorectal Cancer

Interventions: Drug: mFOLFOX6 + panitumumab combination therapy
Drug: mFOLFOX6 + bevacizumab combination therapy

First Posted Date: 2021-09-01

Last Posted Date: 2024-11-20

Lead Sponsor: Takeda

Target Recruit Count: 787

Registration Number: NCT05030493

Locations: 🇯🇵
Takeda selected site, Tokyo, Japan

A Study of Teduglutide in Japanese Children With Short Bowel Syndrome Aged 4 Months or Older

Phase 3

Completed

Conditions: Short Bowel Syndrome

Interventions: Drug: Teduglutide

First Posted Date: 2021-08-30

Last Posted Date: 2024-05-16

Lead Sponsor: Takeda

Target Recruit Count: 3

Registration Number: NCT05027308

Locations: 🇯🇵
University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan
🇯🇵
Kagoshiha University Hospital, Kagoshima, Japan
🇯🇵
Tohoku University Hospital, Sendai, Miyagi, Japan

and more 3 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy